Abiopharma

🔍 Green Park & Golf Ventures II, LLC (Executive)

Company: Mobia Medical, Inc. (MOBI)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 11,139 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 11,139.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 29,704 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 29,704.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 21,819 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 51,523.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 10,000 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 61,523.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Acquired 22,278 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 22,278.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Acquired 10,909 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 33,187.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Acquired 8,500 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 41,687.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Acquired 141,054 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 141,054.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 96,540 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 96,540.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Acquired 112,843 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 209,383.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Acquired 108,005 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 317,388.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Acquired 33,333 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 350,721.00 | transaction_form_type: 4 | Footnotes: F4, F7
• Acquired 68,044 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 68,044.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Acquired 200,202 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 268,246.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 11,139 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 29,704 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F3
• Sold 21,819 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F3
• Sold 10,000 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F3
• Sold 22,278 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F5
• Sold 10,909 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F5
• Sold 8,500 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F5
• Sold 141,054 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F6
• Sold 96,540 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F7
• Sold 112,843 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F7
• Sold 108,005 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F7
• Sold 33,333 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F7
• Sold 68,044 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F8
• Sold 200,202 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F8

Footnotes:

• F1: Each share of Series D Preferred Stock, Series F Preferred Stock, Series E-1 Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Issuer's initial public offering (the "Offering") pursuant to its terms.
• F2: The securities are held by GPG BFH, LLC ("BFH").
• F3: The securities are held by GPG Charles & Potomac, LLC ("C&P").
• F4: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Offering. The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
• F5: The securities are held by GPG Dais, LLC ("Dais").
• F6: The securities are held by GPG GR, LLC ("GR").
• F7: The securities are held by GPG Healthcare Opportunities Fund II, LLC ("HOF II").
• F8: The securities are held by GPG Healthcare Opportunities Fund, LLC ("HOF").
• F9: Green Park & Golf Ventures II, LLC ("GPG Ventures II") is the managing member of each of BFH, C&P, Dais, GR, HOF, and HOF II. Clay M. Heighten, MD, Carl D. Soderstrom and Gilbert G. Garcia II are managers of GPG Ventures II and share voting and dispositive power with respect to the shares held by each of BFH, C&P, Dais, GR, HOF, and HOF II, and as a result may be deemed to beneficially own such securities.
• REMARKS: This Form 4 is the first of five Forms 4 filed relating to the same event. Combined, the five Forms 4 report the holdings for the following reporting persons: Green Park & Golf Ventures II, LLC, Clay M. Heighten, MD, Carl D. Soderstrom, Gilbert G. Garcia II, GPG BFH, LLC, GPG Charles & Potomac, LLC, GPG Dais, LLC, GPG GR, LLC, GPG Healthcare Opportunities Fund II, LLC, GPG Healthcare Opportunities Fund, LLC, GPG JCT, LLC, GPG MTI 22, LLC, GPG MTI 25, LLC, GPG MOBI, LLC, GPG MTI 3-17 Investment, LLC, GPG PHL, LLC, GPG RM Investment, LLC, GPG SC, LLC, GPG WG, LLC, GPG MTIF, LLC, Micro TI Investment 2, LLC, Micro TI Investment, LLC, MTI 20 Investment, LLC, MTI 2015 Investment, LLC, HTX MCT1 0320 Investment, LLC, HTX MCT2 0221 Investment, LLC, HTX MCT3 0322 Investment, LLC, HTX MCT4 0226 Investment, LLC and Green Park & Golf Ventures - Houston, LLC. The Form 4 has been split into five filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons.